Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
The growing number of medications used to treat attention-deficit/hyperactivity disorder
(ADHD) raises important questions about whether different medications have similar or
different therapeutic mechanisms of action. We have recently shown that the stimulant
methylphenidate (MPH) and the non-stimulant atomoxetine (ATX) produce clinical improvement
via a common mechanism in motor cortex, and distinct actions in frontostriatal and midline
cingulate-precuneus regions. These exciting findings offer a window into the common and
unique neurophysiological mechanisms of response to stimulant and non-stimulant treatments.
However, the interpretation and clinical utility of these results would be greatly enhanced
by in-depth investigation of the impact of the two treatments on relevant neural networks,
and analyses which evaluate whether improvement is achieved via normalization or other
adaptive changes in brain function.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Atomoxetine Hydrochloride Central Nervous System Stimulants Methylphenidate